Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease

Neurology. 2007 Mar 20;68(12):911-5. doi: 10.1212/01.wnl.0000257089.50476.92.

Abstract

Background: There is a high incidence of hip fractures in patients with Parkinson disease (PD). Bone mineral density (BMD) is decreased in patients with PD, correlating with the immobilization-induced bone resorption and hypovitaminosis D with compensatory hyperparathyroidism.

Objective: To evaluate the effectiveness of risedronate, an inhibitor of bone resorption, on osteoporosis and the risk of hip fractures in elderly men with PD.

Methods: This was a 2-year, randomized, double-blind, placebo-controlled trial. In a prospective study of patients with PD, 121 patients received a daily dose of 2.5 mg risedronate and vitamin D2 1,000 IU for 2 years, and the remaining 121 received placebo and vitamin D2 1,000 IU. Incidence of hip fractures was compared between the two groups.

Results: Nine patients sustained hip fractures in the placebo group, and three hip fractures occurred in the risedronate group. The relative risk of a hip fracture in the risedronate group vs the placebo group was 0.33 (95% CI, 0.09 to 1.20). BMD increased by 2.2% in the risedronate group and decreased by 2.9% in the placebo group (p < 0.0001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 46.7% in the risedronate group and by 33.0% in the placebo group.

Conclusion: Treatment with risedronate and vitamin D2 increases bone mineral density in elderly men with Parkinson disease and reduces the risk of hip fractures.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amino Acids / urine
  • Biomarkers / urine
  • Bone Density / drug effects
  • Bone Density / physiology
  • Bone Density Conservation Agents / administration & dosage
  • Bone Resorption / drug therapy
  • Bone Resorption / etiology
  • Bone Resorption / physiopathology
  • Double-Blind Method
  • Ergocalciferols / administration & dosage*
  • Etidronic Acid / administration & dosage
  • Etidronic Acid / analogs & derivatives*
  • Hip Fractures / etiology
  • Hip Fractures / prevention & control*
  • Humans
  • Hyperparathyroidism / complications
  • Hyperparathyroidism / physiopathology
  • Male
  • Osteoporosis / drug therapy*
  • Osteoporosis / etiology
  • Osteoporosis / physiopathology
  • Parkinson Disease / complications*
  • Parkinson Disease / physiopathology
  • Placebo Effect
  • Prospective Studies
  • Risedronic Acid
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome
  • Vitamin D Deficiency / complications
  • Vitamin D Deficiency / physiopathology

Substances

  • Amino Acids
  • Biomarkers
  • Bone Density Conservation Agents
  • Ergocalciferols
  • deoxypyridinoline
  • Risedronic Acid
  • Etidronic Acid